Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

Advisory committee recommends approval of Pletal

July 14, 1998

New thrombin inhibitors synthesized at Merck & Co.

July 13, 1998

Absence of cardiodepressive effects with beraprost

July 13, 1998

Cor Therapeutics patents novel factor Xa inhibitors

July 9, 1998

Abciximab treatment validated for prevention of ischemic complications after coronary intervention

July 9, 1998

Cor Therapeutics describes selective factor Xa inhibitors

July 8, 1998

Platelet aggregation inhibitors in development at Meiji Seika

July 6, 1998

FDA advisory committee to review Pletal NDA next week

July 3, 1998

Zeria discloses new thromboxane antagonists for thrombosis

July 3, 1998

HMR introduces Refludan in U.S.

July 2, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Nov. 8, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for November 8, 2024.
Sales balloon for GLP-1 drugs from Novo Nordisk, Eli Lilly
BioWorld
Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide-1 (GLP-1) drugs to treat obesity....
Regulatory actions for Oct. 31, 2024
BioWorld
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Capsida, Electra,...
Australia reimburses Vazkepa a decade after US approval
BioWorld
For the first time, Australians have access to CSL Inc.’s Vazkepa (icosapent ethyl/Vascepa) for managing cardiovascular disease more than a decade after the drug...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.